Ponatinib hydrochloride
Based on 56 publication(s) in Google Scholar
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.76%
- CAS No.: 1114544-31-8
- Formule: C29H28ClF3N6O
- Masse moléculaire:569.02
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ponatinib hydrochloride
More- Cancer Discov. 2021 Jan;11(1):126-141. [Abstract]
- Nat Immunol. 2026 Apr;27(4):738-749. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
- MedComm (2020). 2026 Apr 26:7:e70747. [Abstract]
- Adv Sci (Weinh). 2026 Mar 1:e17231. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- Phytomedicine. 2026 Jun:155:158069. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Int J Biol Macromol. 2025 Jan:286:138305. [Abstract]
- J Med Chem. 2024 Nov 28;67(22):20571-20579. [Abstract]
- J Med Chem. 2019 May 23;62(10):5006-5024. [Abstract]
- J Ethnopharmacol. 2025 Sep 17;355(Pt A):120621. [Abstract]
- J Ethnopharmacol. 2024 Apr 6:323:117669. [Abstract]
- J Ethnopharmacol. 2023 Jun 12:309:116275. [Abstract]
- Neurosci Bull. 2020 Mar;36(3):263-276. [Abstract]
- Biochem Pharmacol. 2021 Oct:192:114710. [Abstract]
- Pharm Biol. 2026 Dec;64(1):67-86. [Abstract]
- Commun Biol. 2024 Jul 10;7(1):843. [Abstract]
- Pharmaceuticals (Basel). 2022 Aug 29;15(9):1073. [Abstract]
- Eur J Pharmacol. 2020 Dec 15:889:173292. [Abstract]
- Int J Mol Sci. 2026 Jun 9;27(12):5217. [Abstract]
- J Hypertens. 2025 May 1;43(5):827-840. [Abstract]
- Biomolecules. 2022 Jun 11;12(6):819. [Abstract]
- BMC Chem. 2025 Aug 22;19(1):248. [Abstract]
- Target Oncol. 2020 Oct;15(5):659-671. [Abstract]
- Transl Oncol. 2026 Jul:69:102819. [Abstract]
- Sci Rep. 2025 Oct 16;15(1):36227. [Abstract]
- Sci Rep. 2025 Jul 2;15(1):22961. [Abstract]
- Cancer Sci. 2025 Apr;116(4):1115-1125. [Abstract]
- J Inflamm Res. 2025 Jun 26:18:8447-8475. [Abstract]
- Clin Chim Acta. 2018 May:480:180-185. [Abstract]
- PLoS One. 2024 Nov 1;19(11):e0308647. [Abstract]
- PLoS One. 2022 Feb 14;17(2):e0263822. [Abstract]
- PLoS One. 2021 Sep 30;16(9):e0258140. [Abstract]
- Fundam Clin Pharmacol. 2021 Oct;35(5):919-929. [Abstract]
- Exp Hematol. 2014 May;42(5):369-379.e3. [Abstract]
- Biomed Rep. 2026 Jun 24;25(2):99. [Abstract]
- J Chem Eng Data. 2024 Jun 10.
- Leuk Res. 2016 Jun:45:24-32. [Abstract]
- Pharmacogn Mag. 2023 Jul 20.
- Blood Neoplasia. 2026 Apr 9;3(3):100230. [Abstract]
- chemRxiv. 2026 Apr 6.
- Blood Vessel Thromb Hemost. 2025 Nov 17.
- bioRxiv. 2025 Sep 30.
- Biomed Pharmacother. 2025 Aug:189:118246. [Abstract]
- bioRxiv. 2025 May 5:2025.04.30.651490. [Abstract]
- University of Pittsburgh. 2025.
- bioRxiv. 2025 Apr 28:2024.04.18.590103. [Abstract]
- bioRxiv. 2025 February 26.
- Biomed Pharmacother. 2024 Nov:180:117569. [Abstract]
- Heliyon. 2024 Sep 28;10(19):e38637. [Abstract]
- Research Square Print. 2023 Mar 23.
- Research Square Preprint. 2021 May.
- Technical University of Munich. 24.01.2018.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
|
LYN 0.24 nM (IC50) |
Abl 0.37 nM (IC50) |
PDGFRα 1.1 nM (IC50) |
VEGFR2 1.5 nM (IC50) |
FGFR1 2.2 nM (IC50) |
Src 5.4 nM (IC50) |
Ponatinib hydrochloride (0.11, 017 μM, 24-48 h) can reduce the viability, migration, and function of human endothelial cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVEC
-
Concentration:0-20 μM
-
Incubation Time:48 h
-
Result:Decreased cell viability in a dose-dependent manner with IC50 value of 0.55 μM.
-
Cell Line:HUVEC
-
Concentration:0.11, 0.17 μM
-
Incubation Time:24 h
-
Result:Increased the percentage of annexin/PI labeled cells.
-
Cell Line:HUVEC
-
Concentration:0.17 μM
-
Incubation Time:20 h
-
Result:Reduced VEGF-induced migration from 100% to 62.3 ± 4.8%.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Influenza A Virus Infected Mice[3]
-
Dosage:200 μL, dissolved in 25 mM citrate buffer (pH 2.75)
-
Administration:p.o.
-
Result:Had higher survival rates and reduced the infiltration of neutrophils.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1114544-31-8
-
Appearance Solid
-
Masse moléculaire 569.02
-
Formule C29H28ClF3N6O
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CC=C(C)C(C#CC2=CN=C3C=CC=NN23)=C1)NC4=CC=C(CN5CCN(CC5)C)C(C(F)(F)F)=C4.Cl
-
Synonyms
AP24534 hydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (56)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
2021 Jan;11(1):126-141. PMID: 33004339 -
Nat Immunol
Sparcl1 mitigates abdominal aortic aneurysm through inhibiting lymphangiogenesis-mediated TLS formation. [Abstract]2026 Apr;27(4):738-749. PMID: 41760906 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Acta Pharm Sin B
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]2023 Oct;13(10):4253-4272. PMID: 37799380
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
BxPC-3, PANC-1 and H6c7 cells were treated with ponatinib (0.1–20 μM) for 24 h, and then cell viability was analyzed by CCK-8 assay.
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
PANC-1 cells were treated with Ponatinib (5-20 μM) or Perifosine (30-70 μM) for 24 h, and total cellular extracts were subjected to Western blot analyses using antibodies against GSDMD and β-tubulin.
-
MedComm (2020)
BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ. [Abstract]2026 Apr 26:7:e70747. PMID: 42051376 -
Adv Sci (Weinh)
BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. [Abstract]2026 Mar 1:e17231. PMID: 41764406 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
Phytomedicine
Huang-Qi-Long-Dan Granule alleviates ischemic stroke injury by regulating the crosstalk between Nrf2 and NF-κB signaling. [Abstract]2026 Jun:155:158069. PMID: 41861685 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Int J Biol Macromol
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. [Abstract]2025 Jan:286:138305. PMID: 39631575
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:286:138305. [Abstract]
KBM5-T315I cells were treated with the indicated concentrations of CX-4945, Ponatinib (0.001-10 μM), or with two combined drugs by simultaneously increasing their concentration at the ratio of 1:500 for Ponatinib + CX-4945. Viability was assessed by the MTT method after 48 h treatment and expressed as percentage of vehicle-treated controls.
-
J Med Chem
2024 Nov 28;67(22):20571-20579. PMID: 39513680 -
J Med Chem
Discovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). [Abstract]2019 May 23;62(10):5006-5024. PMID: 31046271 -
J Ethnopharmacol
Reinwardtia indica Dumort. protects against ponatinib-induced cerebral ischemia in adult zebrafish via attenuation of oxidative stress, neuroinflammation, mitochondrial dysfunction, and neurotransmitter dysregulation: A multi-target therapeutic strategy. [Abstract]2025 Sep 17;355(Pt A):120621. PMID: 40972727 -
J Ethnopharmacol
Alleviation of endothelial dysfunction of Pheretima guillemi (Michaelsen)-derived protein DPf3 in ponatinib-induced thrombotic zebrafish and mechanisms explored through ox-LDL-induced HUVECs and TMT-based proteomics. [Abstract]2024 Apr 6:323:117669. PMID: 38159828 -
J Ethnopharmacol
Determining the chemical profile of Caragana jubata (Pall.) Poir. by UPLC-QTOF-MS analysis and evaluating its anti-ischemic stroke effects. [Abstract]2023 Jun 12:309:116275. PMID: 36806344 -
Neurosci Bull
2020 Mar;36(3):263-276. PMID: 31664678 -
Biochem Pharmacol
Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib. [Abstract]2021 Oct:192:114710. PMID: 34339712 -
Pharm Biol
The role of salvianolic acid B and benzoylpaeoniflorin in enhancing angiogenesis through Nrf2/HO-1/VEGFA signaling axis in ischemic stroke recovery. [Abstract]2026 Dec;64(1):67-86. PMID: 41433220 -
Commun Biol
Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK. [Abstract]2024 Jul 10;7(1):843. PMID: 38987326 -
Pharmaceuticals (Basel)
Discovering a Multi-Component Combination against Vascular Dementia from Danshen-Honghua Herbal Pair by Spectrum-Effect Relationship Analysis. [Abstract]2022 Aug 29;15(9):1073. PMID: 36145294 -
Eur J Pharmacol
2020 Dec 15:889:173292. PMID: 32668288 -
Int J Mol Sci
Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells. [Abstract]2026 Jun 9;27(12):5217. PMID: 42352940 -
J Hypertens
KAT7 contributes to ponatinib-induced hypertension by promoting endothelial senescence and inflammatory responses through activating NF-κB signaling pathway. [Abstract]2025 May 1;43(5):827-840. PMID: 40084466 -
Biomolecules
Investigating the Effect of Tyrosine Kinase Inhibitors on the Interaction between Human Serum Albumin by Atomic Force Microscopy. [Abstract]2022 Jun 11;12(6):819. PMID: 35740944 -
BMC Chem
Integrating analytical quality by design into bioanalytical method development: an HPLC-FLD method for quantification of alectinib in biological matrix. [Abstract]2025 Aug 22;19(1):248. PMID: 40847406 -
Target Oncol
In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features. [Abstract]2020 Oct;15(5):659-671. PMID: 32780298 -
Transl Oncol
A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association. [Abstract]2026 Jul:69:102819. PMID: 42143470 -
Sci Rep
2025 Oct 16;15(1):36227. PMID: 41102354 -
Sci Rep
Unraveling chain specific ubiquitination in cells using tandem ubiquitin binding entities. [Abstract]2025 Jul 2;15(1):22961. PMID: 40595035 -
Cancer Sci
CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway. [Abstract]2025 Apr;116(4):1115-1125. PMID: 39905783 -
J Inflamm Res
Qimai Feiluoping Decoction Inhibits EndMT to Alleviate Pulmonary Fibrosis by Reducing PI3K/AKT/mTOR Pathway-Mediated the Restoration of Autophagy. [Abstract]2025 Jun 26:18:8447-8475. PMID: 40589610 -
Clin Chim Acta
Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. [Abstract]2018 May:480:180-185. PMID: 29458050 -
PLoS One
A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]2024 Nov 1;19(11):e0308647. PMID: 39485774 -
PLoS One
Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma. [Abstract]2022 Feb 14;17(2):e0263822. PMID: 35157705 -
PLoS One
Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence. [Abstract]2021 Sep 30;16(9):e0258140. PMID: 34591931 -
Fundam Clin Pharmacol
2021 Oct;35(5):919-929. PMID: 33523504 -
Exp Hematol
Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. [Abstract]2014 May;42(5):369-379.e3. PMID: 24486648
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Exp Hematol. 2014 May;42(5):369-379.e3. [Abstract]
Phosphorylation levels of F/P (or its mutant), STAT5, or ERK in lysates of CMPs expressing Hes1 with F/P, F/P-D842V, or F/P-T674I, which have been treated with indicated doses of Ponatinib (0.1-1 μM) for 15 min. Data are representative of three independent experiments.
-
Biomed Rep
Toxicity evaluation and anti-ischemic stroke activity of selected natural extracts in zebrafish. [Abstract]2026 Jun 24;25(2):99. PMID: 42388451 -
-
Leuk Res
BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells. [Abstract]2016 Jun:45:24-32. PMID: 27070757 -
-
Blood Neoplasia
From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. [Abstract]2026 Apr 9;3(3):100230. PMID: 42294111 -
-
-
-
Biomed Pharmacother
Identification of nsp16 inhibitors of SARS -CoV-2, SARS -CoV-1 and MERS-CoV from FDA-approved drugs using in silico and in vitro methods. [Abstract]2025 Aug:189:118246. PMID: 40543162 -
bioRxiv
Identification of a RIPK2-Regulated Gene Signature as a Candidate Biomarker for RIPK2 Activity and Prognosis in Prostate Cancer. [Abstract]2025 May 5:2025.04.30.651490. PMID: 40654646 -
-
bioRxiv
2025 Apr 28:2024.04.18.590103. PMID: 38659924 -
-
Biomed Pharmacother
Buparlisib and ponatinib inhibit aggressiveness of cholangiocarcinoma cells via suppression of IRS1-related pathway by targeting oxidative stress resistance. [Abstract]2024 Nov:180:117569. PMID: 39418964
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117569. [Abstract]
Ponatinib inhibited proliferation of CCA cell lines. Relative viability (%) of KKU-100 and KKU-213A cells after 48 h treatment with buparlisib, Ponatinib and the combination of both drugs (0.25-5 μM).
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117569. [Abstract]
Intracellular ROS in KKU-100 and KKU-213A cells after exposure to 0.75 μM Buparlisib, 0.75 μM Ponatinib and the combination of both for 6 h was measured by fluorescence microscopy using DCFH-DA staining.
Ponatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117569. [Abstract]
Representative image of tumors dissected from KKU-213A xenograft mice after 14 days of treatment with Buparlisib (15 mg/kg/day), Ponatinib (30 mg/kg/day) and their combination.
-
Heliyon
Quality by design-based approach for the development of an analytical method for quantifying ponatinib in rat plasma. [Abstract]2024 Sep 28;10(19):e38637. PMID: 39403541 -
-
-
Solvant et solubilité
DMSO : 25 mg/mL (43.94 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. [Content Brief]
[2]. Gover-Proaktor A, et al. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma. 2017 Jun;58(6):1455-1467. [Content Brief]
[3]. Hong YP, et al. Effects of Castanospermine on Inflammatory Response in a Rat Model of Experimental Severe Acute Pancreatitis. Arch Med Res. 2016 Aug;47(6):436-445. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7574 mL | 8.7870 mL | 17.5741 mL | 43.9352 mL |
| 5 mM | 0.3515 mL | 1.7574 mL | 3.5148 mL | 8.7870 mL | |
| 10 mM | 0.1757 mL | 0.8787 mL | 1.7574 mL | 4.3935 mL | |
| 15 mM | 0.1172 mL | 0.5858 mL | 1.1716 mL | 2.9290 mL | |
| 20 mM | 0.0879 mL | 0.4394 mL | 0.8787 mL | 2.1968 mL | |
| 25 mM | 0.0703 mL | 0.3515 mL | 0.7030 mL | 1.7574 mL | |
| 30 mM | 0.0586 mL | 0.2929 mL | 0.5858 mL | 1.4645 mL | |
| 40 mM | 0.0439 mL | 0.2197 mL | 0.4394 mL | 1.0984 mL |
Ponatinib hydrochloride Related Classifications
HY-108766 Related Classifications
Powered by Bioz